Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pseudomonas Infections | 23 | 2024 | 622 | 4.700 |
Why?
|
Pseudomonas Vaccines | 9 | 2022 | 24 | 3.310 |
Why?
|
Pseudomonas aeruginosa | 26 | 2024 | 1277 | 2.670 |
Why?
|
Pneumonia, Bacterial | 11 | 2018 | 316 | 1.830 |
Why?
|
Burkholderia Infections | 6 | 2021 | 41 | 1.470 |
Why?
|
Burkholderia | 5 | 2021 | 36 | 1.150 |
Why?
|
Burkholderia cepacia complex | 3 | 2021 | 24 | 1.150 |
Why?
|
Pneumonia, Ventilator-Associated | 5 | 2022 | 279 | 1.110 |
Why?
|
Cystic Fibrosis | 11 | 2024 | 1285 | 1.080 |
Why?
|
Pneumonia | 7 | 2024 | 2143 | 0.920 |
Why?
|
Antibodies, Bacterial | 12 | 2022 | 1469 | 0.910 |
Why?
|
Th17 Cells | 4 | 2022 | 794 | 0.880 |
Why?
|
Bacterial Proteins | 9 | 2022 | 3847 | 0.830 |
Why?
|
Catheter-Related Infections | 3 | 2022 | 273 | 0.700 |
Why?
|
Antigens, Bacterial | 2 | 2018 | 1155 | 0.690 |
Why?
|
Bacteremia | 6 | 2020 | 979 | 0.650 |
Why?
|
Cross Infection | 6 | 2022 | 1422 | 0.640 |
Why?
|
Respiration, Artificial | 6 | 2023 | 2628 | 0.630 |
Why?
|
Lactobacillus | 1 | 2019 | 212 | 0.610 |
Why?
|
Interleukin-17 | 4 | 2018 | 912 | 0.590 |
Why?
|
Hemeproteins | 1 | 2017 | 61 | 0.560 |
Why?
|
Drug Resistance, Bacterial | 3 | 2022 | 1048 | 0.530 |
Why?
|
Point Mutation | 1 | 2021 | 1595 | 0.520 |
Why?
|
Probiotics | 1 | 2019 | 378 | 0.510 |
Why?
|
Colony Count, Microbial | 1 | 2015 | 330 | 0.470 |
Why?
|
Evolution, Molecular | 2 | 2021 | 1886 | 0.470 |
Why?
|
Respiratory Tract Infections | 1 | 2022 | 1010 | 0.460 |
Why?
|
Mandatory Reporting | 1 | 2015 | 123 | 0.460 |
Why?
|
Drug Carriers | 1 | 2018 | 706 | 0.450 |
Why?
|
Flagellin | 3 | 2021 | 124 | 0.450 |
Why?
|
Bacterial Infections | 1 | 2022 | 1390 | 0.440 |
Why?
|
Vaccines, Attenuated | 7 | 2012 | 315 | 0.430 |
Why?
|
Biofilms | 2 | 2018 | 628 | 0.430 |
Why?
|
2-Propanol | 1 | 2013 | 28 | 0.420 |
Why?
|
Flagella | 3 | 2018 | 99 | 0.420 |
Why?
|
Bacterial Vaccines | 3 | 2006 | 401 | 0.400 |
Why?
|
Chlorhexidine | 1 | 2013 | 160 | 0.380 |
Why?
|
Equipment Contamination | 1 | 2013 | 182 | 0.380 |
Why?
|
Disinfectants | 1 | 2013 | 130 | 0.380 |
Why?
|
Corneal Ulcer | 1 | 2012 | 128 | 0.370 |
Why?
|
Ventilators, Mechanical | 4 | 2023 | 288 | 0.370 |
Why?
|
Peptic Ulcer | 2 | 2024 | 217 | 0.360 |
Why?
|
Disinfection | 1 | 2013 | 211 | 0.360 |
Why?
|
Catheters, Indwelling | 1 | 2013 | 426 | 0.350 |
Why?
|
Anesthetics, Inhalation | 3 | 2021 | 574 | 0.350 |
Why?
|
Anti-Bacterial Agents | 11 | 2023 | 7407 | 0.350 |
Why?
|
Neutropenia | 3 | 2012 | 885 | 0.340 |
Why?
|
Macrophage Activation Syndrome | 2 | 2022 | 124 | 0.330 |
Why?
|
Lipopolysaccharides | 5 | 2018 | 2206 | 0.330 |
Why?
|
Polysaccharides, Bacterial | 1 | 2012 | 578 | 0.320 |
Why?
|
Sepsis | 4 | 2023 | 2585 | 0.300 |
Why?
|
Lung | 12 | 2021 | 10000 | 0.300 |
Why?
|
O Antigens | 4 | 2010 | 196 | 0.300 |
Why?
|
Stenotrophomonas maltophilia | 2 | 2017 | 18 | 0.290 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2022 | 269 | 0.280 |
Why?
|
Shock, Septic | 2 | 2023 | 768 | 0.260 |
Why?
|
Drug Discovery | 1 | 2014 | 1051 | 0.260 |
Why?
|
Disease Models, Animal | 15 | 2018 | 18252 | 0.260 |
Why?
|
Virulence | 6 | 2021 | 1303 | 0.250 |
Why?
|
Mice | 29 | 2024 | 81525 | 0.250 |
Why?
|
Administration, Intranasal | 4 | 2018 | 477 | 0.250 |
Why?
|
UTP-Glucose-1-Phosphate Uridylyltransferase | 1 | 2004 | 6 | 0.240 |
Why?
|
Immunocompromised Host | 2 | 2012 | 856 | 0.240 |
Why?
|
Eye Infections, Bacterial | 3 | 2006 | 242 | 0.240 |
Why?
|
Mice, Inbred C3H | 6 | 2012 | 915 | 0.230 |
Why?
|
Animals | 33 | 2024 | 168459 | 0.220 |
Why?
|
Intensive Care Units | 5 | 2023 | 3745 | 0.220 |
Why?
|
Immune Sera | 2 | 2022 | 606 | 0.220 |
Why?
|
Alkyl and Aryl Transferases | 2 | 2005 | 86 | 0.210 |
Why?
|
Antibodies, Neutralizing | 1 | 2012 | 1943 | 0.200 |
Why?
|
Mice, Inbred C57BL | 11 | 2021 | 22169 | 0.200 |
Why?
|
Staphylococcus aureus | 3 | 2015 | 1458 | 0.190 |
Why?
|
Surgical Wound Infection | 2 | 2021 | 1527 | 0.190 |
Why?
|
High-Frequency Ventilation | 1 | 2001 | 88 | 0.190 |
Why?
|
Toll-Like Receptor 5 | 1 | 2021 | 42 | 0.190 |
Why?
|
Bacterial Load | 2 | 2018 | 152 | 0.180 |
Why?
|
Work Capacity Evaluation | 1 | 2020 | 44 | 0.180 |
Why?
|
Cornea | 3 | 2016 | 1333 | 0.170 |
Why?
|
Vaccines, Synthetic | 2 | 2018 | 616 | 0.170 |
Why?
|
Anti-Ulcer Agents | 1 | 2020 | 112 | 0.170 |
Why?
|
Keratitis | 2 | 2016 | 241 | 0.160 |
Why?
|
Histamine H2 Antagonists | 1 | 2020 | 166 | 0.160 |
Why?
|
Drug Resistance, Microbial | 1 | 2022 | 825 | 0.160 |
Why?
|
General Practitioners | 1 | 2020 | 101 | 0.160 |
Why?
|
Phagocytosis | 5 | 2018 | 1528 | 0.160 |
Why?
|
Vaccines, Subunit | 1 | 2018 | 161 | 0.150 |
Why?
|
Isoflurane | 2 | 2021 | 384 | 0.150 |
Why?
|
Antibody Formation | 1 | 2022 | 1395 | 0.150 |
Why?
|
Child | 19 | 2023 | 80153 | 0.140 |
Why?
|
Peritoneal Cavity | 1 | 2017 | 135 | 0.140 |
Why?
|
Anaerobiosis | 1 | 2017 | 138 | 0.140 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2024 | 1116 | 0.140 |
Why?
|
Bacterial Outer Membrane Proteins | 2 | 2018 | 406 | 0.140 |
Why?
|
Lac Operon | 1 | 2017 | 237 | 0.140 |
Why?
|
Selection, Genetic | 3 | 2017 | 868 | 0.140 |
Why?
|
Total Quality Management | 1 | 1998 | 265 | 0.140 |
Why?
|
Swimming | 1 | 2018 | 208 | 0.140 |
Why?
|
Cephalosporins | 1 | 2017 | 198 | 0.140 |
Why?
|
Genome, Bacterial | 2 | 2019 | 783 | 0.130 |
Why?
|
Antacids | 1 | 2016 | 94 | 0.130 |
Why?
|
Urinary Tract Infections | 1 | 2022 | 802 | 0.130 |
Why?
|
Phylogeny | 3 | 2019 | 2811 | 0.130 |
Why?
|
Macrophage-1 Antigen | 1 | 2017 | 285 | 0.130 |
Why?
|
Intestinal Diseases | 1 | 2020 | 504 | 0.130 |
Why?
|
Cytokines | 4 | 2019 | 7396 | 0.130 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2017 | 377 | 0.130 |
Why?
|
Eye Infections, Fungal | 1 | 2016 | 100 | 0.130 |
Why?
|
Vaccination | 2 | 2012 | 3384 | 0.130 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2017 | 238 | 0.120 |
Why?
|
Digestive System Surgical Procedures | 1 | 2020 | 572 | 0.120 |
Why?
|
Heart Defects, Congenital | 2 | 2024 | 4671 | 0.120 |
Why?
|
Acetylglucosamine | 1 | 2016 | 189 | 0.120 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2015 | 39 | 0.120 |
Why?
|
Humans | 46 | 2024 | 761504 | 0.120 |
Why?
|
Catheterization, Central Venous | 1 | 2020 | 527 | 0.120 |
Why?
|
Antilymphocyte Serum | 1 | 2016 | 487 | 0.120 |
Why?
|
Infant | 11 | 2024 | 36192 | 0.120 |
Why?
|
Hydrocephalus | 1 | 2021 | 764 | 0.120 |
Why?
|
Spleen | 2 | 2012 | 2295 | 0.120 |
Why?
|
Neutrophils | 5 | 2021 | 3767 | 0.110 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 3810 | 0.110 |
Why?
|
Eye Infections | 1 | 2014 | 62 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1334 | 0.110 |
Why?
|
Quality Improvement | 3 | 2023 | 3801 | 0.110 |
Why?
|
Infant, Newborn | 10 | 2023 | 26198 | 0.110 |
Why?
|
Blood-Air Barrier | 1 | 2012 | 24 | 0.110 |
Why?
|
Diarrhea | 1 | 2019 | 1318 | 0.100 |
Why?
|
Trehalose | 1 | 2013 | 88 | 0.100 |
Why?
|
8,11,14-Eicosatrienoic Acid | 1 | 2012 | 64 | 0.100 |
Why?
|
Immunoglobulin G | 2 | 2022 | 4544 | 0.100 |
Why?
|
Macrophages | 2 | 2021 | 5769 | 0.100 |
Why?
|
Genes, Bacterial | 2 | 2018 | 1073 | 0.100 |
Why?
|
Blood | 1 | 2015 | 596 | 0.100 |
Why?
|
Mutation | 7 | 2022 | 30052 | 0.100 |
Why?
|
Arachidonate 12-Lipoxygenase | 1 | 2012 | 82 | 0.100 |
Why?
|
Receptors, Interleukin-17 | 1 | 2012 | 82 | 0.100 |
Why?
|
Blood Bactericidal Activity | 1 | 2012 | 124 | 0.100 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2014 | 1126 | 0.100 |
Why?
|
Female | 28 | 2021 | 392644 | 0.100 |
Why?
|
Transendothelial and Transepithelial Migration | 1 | 2012 | 100 | 0.100 |
Why?
|
Plant Diseases | 1 | 2013 | 178 | 0.100 |
Why?
|
Genetic Variation | 2 | 2019 | 6567 | 0.100 |
Why?
|
Survival Analysis | 4 | 2018 | 10090 | 0.100 |
Why?
|
Mice, Knockout | 6 | 2017 | 14414 | 0.090 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 698 | 0.090 |
Why?
|
Epithelial Cells | 2 | 2021 | 3673 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2017 | 3597 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1560 | 0.090 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2017 | 1133 | 0.090 |
Why?
|
Enteral Nutrition | 1 | 2016 | 794 | 0.090 |
Why?
|
Eye | 1 | 2014 | 712 | 0.090 |
Why?
|
Critical Illness | 4 | 2024 | 2723 | 0.090 |
Why?
|
Retrospective Studies | 12 | 2023 | 80636 | 0.090 |
Why?
|
Flow Cytometry | 2 | 2018 | 5869 | 0.080 |
Why?
|
Arabidopsis | 1 | 2013 | 465 | 0.080 |
Why?
|
Biomedical Research | 1 | 2005 | 3429 | 0.080 |
Why?
|
Adaptive Immunity | 1 | 2014 | 726 | 0.080 |
Why?
|
Immunity, Innate | 3 | 2009 | 3065 | 0.080 |
Why?
|
Immunization | 3 | 2018 | 1228 | 0.080 |
Why?
|
Cell Line | 3 | 2018 | 15601 | 0.080 |
Why?
|
Immunotherapy | 2 | 2016 | 4652 | 0.080 |
Why?
|
Rabbits | 3 | 2006 | 4772 | 0.080 |
Why?
|
Serotyping | 1 | 2008 | 325 | 0.080 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2015 | 846 | 0.080 |
Why?
|
Caveolin 1 | 1 | 2009 | 256 | 0.070 |
Why?
|
Intensive Care Units, Pediatric | 3 | 2022 | 1017 | 0.070 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 8002 | 0.070 |
Why?
|
Disease Outbreaks | 1 | 2017 | 1749 | 0.070 |
Why?
|
3-Phosphoshikimate 1-Carboxyvinyltransferase | 2 | 2005 | 6 | 0.070 |
Why?
|
Child, Preschool | 8 | 2021 | 42230 | 0.070 |
Why?
|
Intestines | 1 | 2015 | 1909 | 0.070 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2007 | 175 | 0.070 |
Why?
|
Carrier State | 1 | 2010 | 523 | 0.070 |
Why?
|
Serpins | 1 | 2007 | 247 | 0.060 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5789 | 0.060 |
Why?
|
Phenotype | 2 | 2021 | 16591 | 0.060 |
Why?
|
Staphylococcal Infections | 1 | 2014 | 1408 | 0.060 |
Why?
|
Oxygen | 1 | 2017 | 4227 | 0.060 |
Why?
|
Hospital Mortality | 4 | 2023 | 5294 | 0.060 |
Why?
|
Hexuronic Acids | 1 | 2004 | 145 | 0.060 |
Why?
|
Glucuronic Acid | 1 | 2004 | 150 | 0.060 |
Why?
|
Clinical Competence | 1 | 2020 | 4792 | 0.060 |
Why?
|
Infection Control | 2 | 2022 | 981 | 0.060 |
Why?
|
Adolescent | 10 | 2021 | 88319 | 0.060 |
Why?
|
Genomics | 1 | 2019 | 5821 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2014 | 4369 | 0.050 |
Why?
|
Lethal Dose 50 | 1 | 2003 | 72 | 0.050 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2008 | 974 | 0.050 |
Why?
|
Pediatrics | 1 | 1998 | 3589 | 0.050 |
Why?
|
Ulcer | 1 | 2024 | 204 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2019 | 15936 | 0.050 |
Why?
|
Hospitals | 3 | 2022 | 3882 | 0.050 |
Why?
|
Urinary Catheterization | 1 | 2022 | 193 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10773 | 0.050 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 450 | 0.050 |
Why?
|
Clindamycin | 1 | 2021 | 139 | 0.050 |
Why?
|
Klebsiella | 1 | 2000 | 49 | 0.040 |
Why?
|
Mice, Inbred Strains | 1 | 2003 | 1762 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2018 | 6075 | 0.040 |
Why?
|
Interleukins | 2 | 2015 | 782 | 0.040 |
Why?
|
Pulmonary Gas Exchange | 1 | 2001 | 379 | 0.040 |
Why?
|
Deoxyribonucleases | 1 | 2001 | 211 | 0.040 |
Why?
|
Cytotoxins | 1 | 2000 | 153 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 10766 | 0.040 |
Why?
|
Sick Leave | 1 | 2020 | 105 | 0.040 |
Why?
|
United States | 5 | 2022 | 72334 | 0.040 |
Why?
|
Gastrointestinal Tract | 1 | 2005 | 833 | 0.040 |
Why?
|
Epidemics | 2 | 2017 | 512 | 0.040 |
Why?
|
Klebsiella Infections | 1 | 2000 | 146 | 0.040 |
Why?
|
Pilot Projects | 2 | 2024 | 8631 | 0.040 |
Why?
|
Intestinal Mucosa | 1 | 2010 | 3032 | 0.040 |
Why?
|
Absenteeism | 1 | 2020 | 247 | 0.040 |
Why?
|
Virulence Factors | 2 | 2013 | 513 | 0.040 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2020 | 264 | 0.040 |
Why?
|
Interleukin-8 | 1 | 2021 | 695 | 0.040 |
Why?
|
Internship and Residency | 1 | 1998 | 5880 | 0.040 |
Why?
|
Ohio | 1 | 1998 | 322 | 0.040 |
Why?
|
Escherichia coli | 2 | 2018 | 4217 | 0.040 |
Why?
|
Bronchoalveolar Lavage | 1 | 2017 | 128 | 0.030 |
Why?
|
Half-Life | 1 | 2017 | 651 | 0.030 |
Why?
|
Abscess | 1 | 2000 | 606 | 0.030 |
Why?
|
Male | 14 | 2021 | 360804 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2021 | 636 | 0.030 |
Why?
|
Mice, Inbred BALB C | 2 | 2002 | 6216 | 0.030 |
Why?
|
Infant, Premature, Diseases | 1 | 2001 | 710 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2024 | 9539 | 0.030 |
Why?
|
Organ Transplantation | 1 | 2005 | 1157 | 0.030 |
Why?
|
Prospective Studies | 4 | 2022 | 54425 | 0.030 |
Why?
|
Neutrophil Infiltration | 1 | 2017 | 390 | 0.030 |
Why?
|
Hospitals, Pediatric | 1 | 2023 | 1860 | 0.030 |
Why?
|
Gene Deletion | 1 | 2002 | 2665 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 11903 | 0.030 |
Why?
|
Host-Pathogen Interactions | 2 | 2013 | 1459 | 0.030 |
Why?
|
Retinal Diseases | 1 | 2000 | 705 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2017 | 983 | 0.030 |
Why?
|
Xylans | 1 | 2013 | 8 | 0.030 |
Why?
|
Equipment Design | 1 | 2001 | 3510 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2018 | 2748 | 0.030 |
Why?
|
Anesthesia, General | 1 | 2020 | 1174 | 0.030 |
Why?
|
alpha-Amylases | 1 | 2013 | 39 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2022 | 20098 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 917 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 1998 | 1156 | 0.030 |
Why?
|
Plants, Genetically Modified | 1 | 2013 | 115 | 0.030 |
Why?
|
Glucans | 1 | 2013 | 68 | 0.030 |
Why?
|
Glucosyltransferases | 1 | 2013 | 96 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2023 | 2220 | 0.030 |
Why?
|
Respiratory Insufficiency | 1 | 2001 | 1230 | 0.030 |
Why?
|
Length of Stay | 2 | 2016 | 6425 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2008 | 18965 | 0.030 |
Why?
|
NF-kappa B | 1 | 2021 | 2490 | 0.030 |
Why?
|
Plant Leaves | 1 | 2013 | 150 | 0.030 |
Why?
|
Logistic Models | 2 | 2017 | 13255 | 0.030 |
Why?
|
Forced Expiratory Volume | 1 | 2017 | 1814 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1886 | 0.030 |
Why?
|
Infant, Premature | 1 | 2001 | 2107 | 0.020 |
Why?
|
Risk Factors | 4 | 2021 | 74206 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2017 | 962 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2017 | 1937 | 0.020 |
Why?
|
Adaptation, Biological | 1 | 2011 | 147 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3826 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2192 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2021 | 2072 | 0.020 |
Why?
|
Cell Wall | 1 | 2013 | 425 | 0.020 |
Why?
|
Ciprofloxacin | 1 | 2011 | 312 | 0.020 |
Why?
|
Lung Diseases | 2 | 2011 | 1909 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 3023 | 0.020 |
Why?
|
Gene Expression | 2 | 2018 | 7581 | 0.020 |
Why?
|
Respiratory Mucosa | 1 | 2012 | 439 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3123 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2011 | 992 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2004 | 9177 | 0.020 |
Why?
|
Immunity, Mucosal | 1 | 2010 | 483 | 0.020 |
Why?
|
Macrophages, Alveolar | 1 | 2009 | 412 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2013 | 1301 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3688 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12341 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2018 | 13446 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41487 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 1998 | 2373 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9646 | 0.020 |
Why?
|
Bacterial Translocation | 1 | 2005 | 73 | 0.020 |
Why?
|
Boston | 1 | 1998 | 9326 | 0.020 |
Why?
|
Adult | 5 | 2022 | 221177 | 0.010 |
Why?
|
Binding Sites, Antibody | 1 | 2004 | 337 | 0.010 |
Why?
|
Cecum | 1 | 2005 | 233 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16981 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2024 | 64680 | 0.010 |
Why?
|
Peroxidase | 1 | 2007 | 609 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2006 | 1060 | 0.010 |
Why?
|
Hybridomas | 1 | 2004 | 442 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12974 | 0.010 |
Why?
|
Immunization, Passive | 1 | 2006 | 616 | 0.010 |
Why?
|
Immunoglobulin Variable Region | 1 | 2004 | 419 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10209 | 0.010 |
Why?
|
Alginates | 1 | 2004 | 248 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2009 | 1787 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 21353 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2005 | 13639 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12463 | 0.010 |
Why?
|
Immunoblotting | 1 | 2005 | 1646 | 0.010 |
Why?
|
Lymphocytes | 1 | 2009 | 2612 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7390 | 0.010 |
Why?
|
Cefotaxime | 1 | 2001 | 35 | 0.010 |
Why?
|
Species Specificity | 1 | 2004 | 2414 | 0.010 |
Why?
|
Transformation, Genetic | 1 | 2000 | 192 | 0.010 |
Why?
|
Liver Abscess | 1 | 2000 | 81 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2017 | 22176 | 0.010 |
Why?
|
Prevalence | 1 | 2016 | 15732 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2005 | 2218 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 23995 | 0.010 |
Why?
|
Young Adult | 2 | 2017 | 59243 | 0.010 |
Why?
|
Models, Animal | 1 | 2005 | 2112 | 0.010 |
Why?
|
HIV Infections | 1 | 2005 | 17351 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14031 | 0.010 |
Why?
|
Laser Coagulation | 1 | 2000 | 330 | 0.010 |
Why?
|
Hospitalization | 1 | 2017 | 10723 | 0.010 |
Why?
|
Endophthalmitis | 1 | 2000 | 260 | 0.010 |
Why?
|
Vitrectomy | 1 | 2000 | 392 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 2001 | 1479 | 0.010 |
Why?
|
DNA Primers | 1 | 2000 | 2819 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 39967 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 15500 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 6534 | 0.010 |
Why?
|
Fluorescein Angiography | 1 | 2000 | 1059 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2000 | 2678 | 0.010 |
Why?
|
Acute Disease | 1 | 2004 | 7237 | 0.010 |
Why?
|
Models, Biological | 1 | 2007 | 9469 | 0.010 |
Why?
|
Visual Acuity | 1 | 2000 | 2672 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2000 | 6310 | 0.010 |
Why?
|
Base Sequence | 1 | 2000 | 12441 | 0.010 |
Why?
|
Middle Aged | 1 | 2017 | 220895 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 20570 | 0.000 |
Why?
|